Funding for this research was provided by:
National Multiple Sclerosis Society (RG 4775A1/1)
Text and Data Mining valid from 2018-05-03
Received: 30 March 2018
Accepted: 16 April 2018
First Online: 3 May 2018
: All experiments were approved by the Academic Medical Center Animal Ethics Committee and complied with the Dutch national policy on humane care and the use of laboratory animals.
: FB, KF and VR are the inventors of patents that describe the use of inhibitors of the terminal complement pathway for therapeutic purposes; they are co-founders of Regenesance BV. FB. is founder of Complement Pharma BV.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.